Skip to main content
Log in

Novel targets for antidepressant therapies

  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Most depressed patients fail to achieve remission despite adequate antidepressant monotherapy, and a substantial minority show minimal improvement despite optimal and aggressive therapy. However, major advances have taken place in elucidating the neurobiology of depression, and several novel targets for antidepressant therapy have emerged. Three primary approaches are currently being taken: 1) optimizing the pharmacologic modulation of monoaminergic neurotransmission, 2) developing medications that target neurotransmitter systems other than the monoamines, and 3) directly modulating neuronal activity via focal brain stimulation. We review novel therapeutic targets for developing improved antidepressant therapies, including triple monoamine reuptake inhibitors, atypical antipsychotic augmentation, dopamine receptor agonists, corticotropin-releasing factor-1 receptor antagonists, glucocorticoid receptor antagonists, substance P receptor antagonists, N-methyl-d-aspartate receptor antagonists, nemifitide, omega-3 fatty acids, and melatonin receptor agonists. Developments in therapeutic focal brain stimulation include vagus nerve stimulation, transcranial magnetic stimulation, magnetic seizure therapy, transcranial direct current stimulation, and deep brain stimulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Dunlop BW, Nemeroff CB: The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007, 64:327–337.

    Article  PubMed  CAS  Google Scholar 

  2. Beer B, Stark J, Krieter P, et al.: DOV 216,303, a “triple” reuptake inhibitor: safety, tolerability, and pharmacokinetic profile. J Clin Pharmacol 2004, 44:1360–1367.

    Article  PubMed  CAS  Google Scholar 

  3. Rascol O, Poewe W, Lees A, et al.: Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study. Arch Neurol 2008, 65:577–583.

    Article  PubMed  Google Scholar 

  4. Bystritsky A, Ackerman DL, Rosen RM, et al.: Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry 2004, 65:565–568.

    Article  PubMed  CAS  Google Scholar 

  5. Bartzokis G, Lu PH, Turner J, et al.: Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry 2005, 57:474–479.

    Article  PubMed  CAS  Google Scholar 

  6. Papakostas GI, Petersen TJ, Nierenberg AA, et al.: Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004, 65:217–221.

    PubMed  CAS  Google Scholar 

  7. Marcus RN, McQuade RD, Carson WH, et al.: The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008, 28:156–165.

    PubMed  CAS  Google Scholar 

  8. Berman RM, Marcus RN, Swanink R, et al.: The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, doubleblind, placebo-controlled study. J Clin Psychiatry 2007, 68:843–853.

    PubMed  CAS  Google Scholar 

  9. Corya SA, Williamson D, Sanger TM, et al.: A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006, 23:364–372.

    Article  PubMed  CAS  Google Scholar 

  10. Calabrese JR, Keck PE Jr, Macfadden W, et al.: A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005, 162:1351–1360.

    Article  PubMed  Google Scholar 

  11. Thase ME, Macfadden W, Weisler RH, et al.: Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006, 26:600–609.

    Article  PubMed  CAS  Google Scholar 

  12. Baune BT, Caliskan S, Todder D: Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression. Hum Psychopharmacol 2007, 22:1–9.

    Article  PubMed  CAS  Google Scholar 

  13. McIntyre A, Gendron A, McIntyre A: Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety 2007, 24:487–494.

    Article  PubMed  CAS  Google Scholar 

  14. Konstantinidis A, Hrubos W, Nirnberger G, et al.: Quetiapine in combination with citalopram in patients with unipolar psychotic depression. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:242–247.

    Article  PubMed  CAS  Google Scholar 

  15. Doree JP, Des Rosiers J, Lew V, et al.: Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Curr Med Res Opin 2007, 23:333–341.

    Article  PubMed  CAS  Google Scholar 

  16. Mahmoud RA, Pandina GJ, Turkoz I, et al.: Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med 2007, 147:593–602.

    PubMed  Google Scholar 

  17. Keitner GI, Garlow SJ, Ryan CE, et al.: A randomized placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat, unipolar, non-psychotic major depression. J Psychiatr Res 2008 Jun 27 (Epub ahead of print).

  18. Zarate CA Jr, Payne JL, Singh J, et al.: Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004, 56:54–60.

    Article  PubMed  CAS  Google Scholar 

  19. Goldberg JF, Burdick KE, Endick CJ: Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004, 161:564–566.

    Article  PubMed  Google Scholar 

  20. Cassano P, Lattanzi L, Soldani F, et al.: Pramipexole in treatment-resistant depression: an extended follow-up. Depress Anxiety 2004, 20:131–138.

    Article  PubMed  CAS  Google Scholar 

  21. Lattanzi L, Dell’Osso L, Cassano P, et al.: Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord 2002, 4:307–314.

    Article  PubMed  CAS  Google Scholar 

  22. Cassano P, Lattanzi L, Fava M, et al.: Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry 2005, 50:357–360.

    PubMed  Google Scholar 

  23. Gutman DA, Owens MJ, Nemeroff CB: Corticotropinreleasing factor receptor and glucocorticoid receptor antagonists: new approaches to antidepressant treatment. In Current and Future Developments in Psychopharmacology. Edited by Den Boer JA, George MS, ter Horst GJ. Amsterdam, The Netherlands: Benecke N.I.; 2005:133–158.

    Google Scholar 

  24. Zobel AW, Nickel T, Kunzel HE, et al.: Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 2000, 34:171–181.

    Article  PubMed  CAS  Google Scholar 

  25. Binneman B, Feltner D, Kolluri S, et al.: A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 2008, 165:617–620.

    Article  PubMed  Google Scholar 

  26. Ising M, Zimmermann US, Kunzel HE, et al.: High-affinity CRF1 receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response. Neuropsychopharmacology 2007, 32:1941–1949.

    Article  PubMed  CAS  Google Scholar 

  27. Murphy BE, Filipini D, Ghadirian AM: Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486. J Psychiatry Neurosci 1993, 18:209–213.

    PubMed  CAS  Google Scholar 

  28. Belanoff JK, Flores BH, Kalezhan M, et al.: Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol 2001, 21:516–521.

    Article  PubMed  CAS  Google Scholar 

  29. Belanoff JK, Rothschild AJ, Cassidy F, et al.: An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 2002, 52:386–392.

    Article  PubMed  CAS  Google Scholar 

  30. Culman J, Unger T: Central tachykinins: mediators of defence reaction and stress reactions. Can J Physiol Pharmacol 1995, 73:885–891.

    PubMed  CAS  Google Scholar 

  31. Kramer MS, Cutler N, Feighner J, et al.: Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998, 281:1640–1645.

    Article  PubMed  CAS  Google Scholar 

  32. Geracioti TD Jr, Carpenter L, Owens MJ, et al.: Elevated cerebrospinal fluid substance P concentrations in post-traumatic stress disorder and major depression. Am J Psychiatry 2006, 163:637–643.

    Article  PubMed  Google Scholar 

  33. Bondy B, Baghai TC, Minov C, et al.: Substance P serum levels are increased in major depression: preliminary results. Biol Psychiatry 2003, 53:538–542.

    Article  PubMed  CAS  Google Scholar 

  34. Keller M, Montgomery S, Ball W, et al.: Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 2006, 59:216–223.

    Article  PubMed  CAS  Google Scholar 

  35. Kramer MS, Winokur A, Kelsey J, et al.: Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004, 29:385–392.

    Article  PubMed  CAS  Google Scholar 

  36. Herpfer I, Lieb K: Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs 2005, 19:275–293.

    Article  PubMed  CAS  Google Scholar 

  37. Furmark T, Appel L, Michelgard A, et al.: Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 2005, 58:132–142.

    Article  PubMed  CAS  Google Scholar 

  38. Chenu F, Guiard BP, Bourin M, et al.: Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test. Behav Brain Res 2006, 172:256–263.

    Article  PubMed  CAS  Google Scholar 

  39. Paul IA, Skolnick P: Glutamate and depression: clinical and preclinical studies. Ann N Y Acad Sci 2003, 1003:250–272.

    Article  PubMed  CAS  Google Scholar 

  40. Sapolsky RM: The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry 2000, 48:755–765.

    Article  PubMed  CAS  Google Scholar 

  41. Rogoz Z, Skuza G, Kusmider M, et al.: Synergistic effect of imipramine and amantadine in the forced swimming test in rats. Behavioral and pharmacokinetic studies. Pol J Pharmacol 2004, 56:179–185.

    PubMed  CAS  Google Scholar 

  42. Stryjer R, Strous RD, Shaked G, et al.: Amantadine as augmentation therapy in the management of treatment-resistant depression. Int Clin Psychopharmacol 2003, 18:93–96.

    Article  PubMed  Google Scholar 

  43. Palucha A, Branski P, Szewczyk B, et al.: Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol Biochem Behav 2005, 81:901–906.

    Article  PubMed  CAS  Google Scholar 

  44. Ostroff R, Gonzales M, Sanacora G: Antidepressant effect of ketamine during ECT. Am J Psychiatry 2005, 162:1385–1386.

    Article  PubMed  Google Scholar 

  45. Zarate CA Jr, Singh JB, Carlson PJ, et al.: A randomized trial of an N-methyl-D-aspartate antagonist in treatmentresistant major depression. Arch Gen Psychiatry 2006, 63:856–864.

    Article  PubMed  CAS  Google Scholar 

  46. Liebrenz M, Stohler R, Borgeat A: Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression. World J Biol Psychiatry 2007, 10:1–4.

    Google Scholar 

  47. Zarate CA Jr, Singh JB, Quiroz JA, et al.: A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006, 163:153–155.

    Article  PubMed  Google Scholar 

  48. Zarate CA Jr, Payne JL, Quiroz J, et al.: An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004, 161:171–174.

    Article  PubMed  Google Scholar 

  49. Zarate CA Jr, Quiroz JA, Singh JB, et al.: An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005, 57:430–432.

    Article  PubMed  CAS  Google Scholar 

  50. Sanacora G, Kendell SF, Levin Y, et al.: Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007, 61:822–825.

    Article  PubMed  CAS  Google Scholar 

  51. Levy MI, DeNigris Y, Davis KL: Rapid antidepressant activity of melanocyte-inhibiting factor: a clinical trial. Biol Psychiatry 1982, 17:259–263.

    PubMed  CAS  Google Scholar 

  52. Montgomery SA, Feighner JP, Sverdlov L, et al.: Efficacy and safety of 30 mg/d and 45 mg/d nemifitide compared to placebo in major depressive disorder. Int J Neuropsychopharmacol 2006, 9:517–528.

    Article  PubMed  CAS  Google Scholar 

  53. Parker G, Gibson NA, Brotchie H, et al.: Omega-3 fatty acids and mood disorders. Am J Psychiatry 2006, 163:969–978.

    Article  PubMed  Google Scholar 

  54. Nemets B, Stahl Z, Belmaker RH: Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002, 159:477–479.

    Article  PubMed  Google Scholar 

  55. Stoll AL, Severus WE, Freeman MP, et al.: Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebocontrolled trial. Arch Gen Psychiatry 1999, 56:407–412.

    Article  PubMed  CAS  Google Scholar 

  56. Keck PE Jr, Mintz J, McElroy SL, et al.: Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry 2006, 60:1020–1022.

    Article  PubMed  CAS  Google Scholar 

  57. Lin PY, Su KP: A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry 2007, 68:1056–1061.

    PubMed  CAS  Google Scholar 

  58. Su KP, Huang SY, Chiu TH, et al.: Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008, 69:644–651.

    Article  PubMed  CAS  Google Scholar 

  59. Rees AM, Austin MP, Parker GB: Omega-3 fatty acids as a treatment for perinatal depression: randomized doubleblind placebo-controlled trial. Aust N Z J Psychiatry 2008, 42:199–205.

    Article  PubMed  Google Scholar 

  60. Lewy AJ, Bauer VK, Cutler NL, et al.: Melatonin treatment of winter depression: a pilot study. Psychiatry Res 1998, 77:57–61.

    Article  PubMed  CAS  Google Scholar 

  61. Dolberg OT, Hirschmann S, Grunhaus L: Melatonin for the treatment of sleep disturbances in major depressive disorder. Am J Psychiatry 1998, 155:1119–1121.

    PubMed  CAS  Google Scholar 

  62. Loo H, Hale A, D’Haenen H: Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002, 17:239–247.

    Article  PubMed  CAS  Google Scholar 

  63. Kennedy SH, Emsley R: Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006, 16:93–100.

    Article  PubMed  CAS  Google Scholar 

  64. Olie JP, Kasper S: Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007, 10:661–673.

    PubMed  CAS  Google Scholar 

  65. Calabrese JR, Guelfi JD, Perdrizet-Chevallier C: Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord 2007, 9:628–635.

    Article  PubMed  CAS  Google Scholar 

  66. Kellner CH, Knapp RG, Petrides G, et al.: Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Arch Gen Psychiatry 2006, 63:1337–1344.

    Article  PubMed  Google Scholar 

  67. Ben-Menachem E: Vagus-nerve stimulation for the treatment of epilepsy. Lancet Neurol 2002, 1:477–482.

    Article  PubMed  Google Scholar 

  68. Sackeim HA, Rush AJ, George MS, et al.: Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology 2001, 25:713–728.

    Article  PubMed  CAS  Google Scholar 

  69. Nahas Z, Marangell LB, Husain MM, et al.: Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry 2005, 66:1097–1104.

    PubMed  Google Scholar 

  70. Rush AJ, Marangell LB, Sackeim HA, et al.: Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005, 58:347–354.

    Article  PubMed  Google Scholar 

  71. Rush AJ, Sackeim HA, Marangell LB, et al.: Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry 2005, 58:355–363.

    Article  PubMed  Google Scholar 

  72. George MS, Rush AJ, Marangell LB, et al.: A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry 2005, 58:364–373.

    Article  PubMed  Google Scholar 

  73. Sackeim HA, Brannan SK, Rush AJ, et al.: Durability of antidepressant response to vagus nerve stimulation (VNS). Int J Neuropsychopharmacol 2007, 10:817–826.

    Article  PubMed  CAS  Google Scholar 

  74. Dunner DL, Rush AJ, Russell JM, et al.: Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry 2006, 67:688–695.

    Article  PubMed  Google Scholar 

  75. Burt T, Lisanby SH, Sackeim HA: Neuropsychiatric applications of transcranial magnetic stimulation: a metaanalysis. Int J Neuropsychopharmacol 2002, 5:73–103.

    Article  PubMed  CAS  Google Scholar 

  76. Klein E, Kreinin I, Chistyakov A, et al.: Therapeutic efficacy of right prefrontal slow repetitive transcranial magnetic stimulation in major depression: a double-blind controlled study. Arch Gen Psychiatry 1999, 56:315–320.

    Article  PubMed  CAS  Google Scholar 

  77. Fitzgerald PB, Brown TL, Marston NA, et al.: Transcranial magnetic stimulation in the treatment of depression: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 2003, 60:1002–1008.

    Article  PubMed  Google Scholar 

  78. Gershon AA, Dannon PN, Grunhaus L: Transcranial magnetic stimulation in the treatment of depression. Am J Psychiatry 2003, 160:835–845.

    Article  PubMed  Google Scholar 

  79. Avery DH, Holtzheimer PE 3rd, Fawaz W, et al.: A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression. Biol Psychiatry 2006, 59:187–194.

    Article  PubMed  Google Scholar 

  80. O’Reardon JP, Solvason HB, Janicak PG, et al.: Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 2007, 62:1208–1216.

    Article  PubMed  Google Scholar 

  81. Lisanby SH, Luber B, Schlaepfer TE, et al.: Safety and feasibility of magnetic seizure therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy. Neuropsychopharmacology 2003, 28:1852–1865.

    Article  PubMed  Google Scholar 

  82. Kosel M, Frick C, Lisanby SH, et al.: Magnetic seizure therapy improves mood in refractory major depression. Neuropsychopharmacology 2003, 28:2045–2048.

    PubMed  Google Scholar 

  83. White PF, Amos Q, Zhang Y, et al.: Anesthetic considerations for magnetic seizure therapy: a novel therapy for severe depression. Anesth Analg 2006, 103:76–80.

    Article  PubMed  Google Scholar 

  84. Boggio PS, Rigonatti SP, Ribeiro RB, et al.: A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression. Int J Neuropsychopharmacol 2008, 11:249–254.

    Article  PubMed  Google Scholar 

  85. Mayberg HS, Lozano AM, Voon V, et al.: Deep brain stimulation for treatment-resistant depression. Neuron 2005, 45:651–660.

    Article  PubMed  CAS  Google Scholar 

  86. Lozano AM, Mayberg HS, Giacobbe P, et al.: Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry 2008, 64:461–467.

    Article  PubMed  Google Scholar 

  87. Greenberg BD, Nahas Z, Carpenter LL: Current status of deep brain stimulation. Prim Psychiatry 2005, 12:59–64.

    Google Scholar 

  88. Schlaepfer TE, Cohen MX, Frick C, et al.: Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology 2008, 33:368–377.

    Article  PubMed  Google Scholar 

  89. Jimenez F, Velasco F, Salin-Pascual R, et al.: A patient with a resistant major depression disorder treated with deep brain stimulation in the inferior thalamic peduncle. Neurosurgery 2005, 57:585–593; discussion 585–593.

    Article  PubMed  Google Scholar 

  90. Sartorius A, Henn FA: Deep brain stimulation of the lateral habenula in treatment resistant major depression. Med Hypotheses 2007, 69:1305–1308.

    Article  PubMed  Google Scholar 

  91. Greenberg BD, Malone DA, Friehs GM, et al.: Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology 2006, 31:2384–2393.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Paul E. Holtzheimer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Holtzheimer, P.E., Nemeroff, C.B. Novel targets for antidepressant therapies. Curr Psychiatry Rep 10, 465–473 (2008). https://doi.org/10.1007/s11920-008-0075-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-008-0075-5

Keywords

Navigation